January 29, 2010 -- Speeding Up Cardiac MR Analysis Workflow and Scar Tissue Analysis with Medis QMass® MR 7.2

Cardiac quantification software supplier Medis today released a new version of its QMass MR software. QMass MR 7.2 makes the analysis workflow faster and offers automatic scar tissue segmentation.

QMass MR is the Medis software solution for the quantitative analysis of cardiac MR. It enables clinicians, researchers and technicians to analyze global and regional cardiac function, scar tissue and viability, and cardiac function at various stress levels.

The new version features many shortcuts and interface improvements that make working with the software faster and more intuitive. Examples are scrolling through series in the Movie Tool and one-click selection of the ED or ES phase in the Study Matrix.

For clinicians or researchers performing cardiac MR scar tissue analysis, QMass MR 7.2 provides two major  improvements.

First of all, scar tissue analysis has become significantly faster because of the introduction of automatic segmentation. While the analysis can still be monitored and modified at each of the four analysis steps, the automatic segmentation reduces manual editing to a minimum.

Secondly, the scar tissue analysis in QMass MR now features double thresholding. This makes it possible to differentiate the infarct core from the peri-infarct region, and quantify those regions.  

Product overview >>

What's New E-Learning Sessions >>

January 29, 2010 -- Medis Releases QFlow 5.2

Today, Medis released a new version of QFlow, its application for the quantification of flow and velocities in phase-contrast MR studies.

In this new version users will find, among other features, even faster contour detection and many improvements in the interface.

QFlow already featured fast, three-click contour detection for regions of interest. In QFlow 5.2, contours for up to four regions of interest can now be detected at once.

Product overview >>

January 18, 2010 -- Medis and MeVis Announce Strategic Alliance

Medis medical imaging systems and MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company with focus on dedicated, disease-oriented clinical applications, today announced a strategic alliance, which may lead up to a potential take-over of Medis by the MeVis Group. As a first step, MeVis has now acquired a minority stake in Medis. Terms of the transaction were not disclosed.

With its renowned products and expertise in the analysis of cardiovascular images, Medis will be a strategic addition for MeVis, expanding MeVis' portfolio of software products for the early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological conditions.

For Medis, the MeVis Group's successful multi-modality technology platform and its similar background in research approach (MeVis has a research relationship with the Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, Germany) make MeVis the ideal partner for a strategic alliance.

The combined research experience in cardiology and radiology, and the utilization of MeVis' technology platform MeVisAP™ and its rapid prototyping platform MeVisLAB™ will ensure the rapid development of software products in the future, providing customers with the latest in both current and new software products.

"The epidemiological impact of cardiovascular disease on the global population makes the Medis products, know-how, and distribution channels a strategically significant addition to our portfolio," states Dr. Carl J.G. Evertsz, Chairman and CEO of MeVis Medical Solutions AG. "We are delighted about this strategic alliance, in which we will collaborate with the Medis team to develop and market new products for the multi-modality diagnosis of cardiovascular disease, and cardiovascular interventions."

"Our strategic partnership with MeVis means an incredibly valuable joining of forces in research, development and sales. Our customers will be able to benefit from the synergy that this partnership with the MeVis Group brings, while continuing to profit from working with familiar, high-quality products in cardiovascular quantification software", says Prof. Dr. Hans Reiber, co-founder and proprietor of Medis.

November 4, 2009 -- QAngio® XA 7.2 Release Brings Innovations in Bifurcation Analysis

Today, Medis releases the new version of its quantitative analysis software for peripheral and coronary vessels in X-ray angiograms, QAngio XA 7.2.

This version features two major innovations in the analysis of bifurcated arteries: dedicated analysis models and edge segment analysis.

QAngio XA 7.2 gives clinicians and researchers two dedicated analysis models for bifurcations. The T-shape and Y-shape analysis models make it possible to handle differences in vessel morphology, device, and intervention strategy.

QAngio XA 7.2 also optionally features analysis results for all stent and ostial edge segments in bifurcated vessels. This allows clinicians and researchers to focus on specific segments of the vessel wall, such as stent edges, ostia of distal branches and the bifurcation core.

The QAngio XA 7.2 innovations make bifurcation analysis more flexible and enable more targeted follow-up of patients after intervention.

More news items in the News Archive >>